HDAC9 and neoplasm: In addition, neratinib / HDAC inhibitor combination therapy enhances the immunogenicity profile of tumor cells possibly unveiling as sensitivity of the remaining tumor cells to immunotherapy agents, such as immune-checkpoint inhibition.